


Sygnia 



Sygnia Itrix Health Innovation Actively Managed ETF

A high-risk, actively managed exchange traded fund which aims to provide investors access to healthcare innovation stocks

Risk profile



Investment objective and strategy

The objective of the Sygnia Itrix Health Innovation Actively Managed ETF is to provide an investment vehicle that gives easy access to investors who want to achieve long-term capital appreciation by gaining exposure to companies positioned at the forefront of healthcare innovation and new technologies. These transformative technologies focus on advancement in healthcare, digital health, and biotech among others. The Sygnia Itrix Health Innovation fund is a high-risk, actively managed exchange traded fund, registered as a collective investments scheme, and is listed on the Johannesburg Stock Exchange.

Risk profile

The fund has a 100% strategic allocation to global equities. The risk in the fund is managed by spreading investments across countries and individual shares, but the structure of the fund is dictated by the largest healthcare innovation companies. The focus on the largest, more liquid companies provides an added benefit in terms of risk management.

What the fund invests in

| Top 10 holdings | Percentage | Allocation |
|------------------------------------|------------|------------|
| Eli Lilly Ord Shs | 10.0 | |
| UnitedHealth Group Ord Shs | 6.1 | |
| Novo Nordisk Ord Shs Class B | 4.6 | |
| Johnson & Johnson Ord Shs | 4.4 | |
| AbbVie Ord Shs | 3.9 | |
| Novo-Nordisk ADR repsg 1 B Ord Shs | 3.4 | |
| Merck & Co Ord Shs | 3.2 | |
| Thermo Fisher Scientific Ord Shs | 2.7 | |
| Astrazeneca Ord Shs | 2.6 | |
| Roche Holding Par Shs | 2.5 | |

Who should invest?

It is a suitable investment for investors seeking higher returns, those willing to tolerate higher volatility and those aiming to maximise capital accumulation over the longer term in the most cost-effective manner. Given the specialist nature of the fund, it should be used as part of a diversified investment strategy rather than as a sole equity investment.

Fees

| | |
|-------------------------------|------------------------|
| Management fee | 0.43% p.a. (excl. VAT) |
| Other expenses | 0.01% (excl. VAT) |
| VAT | 0.07% |
| Total expense ratio (TER) | 0.52% (Sep 2024) |
| Transaction costs (TC) | 0.01% (Sep 2024) |
| Total investment charge (TIC) | 0.53% (Sep 2024) |

A higher TER does not necessarily imply a poor return, nor does a low TER imply a good return. The current TER may not necessarily be an accurate indication of future TERs. TCs are a necessary cost in administering the financial product and impact financial product returns. TCs should not be considered in isolation, as returns may be impacted by many other factors over time, including market returns, the type of financial product, the investment decisions of the investment manager and the TER.

Portfolio managers

Sygnia Asset Management (Pty) Ltd

The management of investments is outsourced to Sygnia Asset Management (Pty) Ltd (FSP 873), an authorised financial services provider under the Financial Advisory and Intermediary Services Act, 2002.

Key facts

Fund launch date

6 August 2021

Fund size

R803 million

Regulation 28

Non-compliant

Benchmark

Solactive Developed Markets Healthcare 150 Index

Minimum investment period

5 years

Disclosures

The Sygnia Group is a member of the Association for Savings and Investment SA. Sygnia Itrix (RF) (Pty) Ltd is a registered and approved Manager under the Collective Investment Schemes Control Act, 2002 (CISCA). Sygnia Asset Management (Pty) Limited (FSP 873), an authorised financial services provider, is the appointed investment manager of the fund. Sygnia Itrix does not provide any guarantee with respect to the capital or return of the portfolio. Collective investment schemes are generally medium- to long-term investments. Collective investment schemes are traded at ruling prices and can engage in borrowing and scrip lending. The value of investments/units may go down as well as up, and past performance is not necessarily an indicator of future performance. AMETFs trade on stock exchanges and may therefore incur additional costs associated with listed securities. Unlike a unit trust, which can be bought or sold only once per day, an AMETF can be traded intraday, during exchange trading hours. AMETFs may invest in foreign securities, which may be exposed to macroeconomic, settlement, political, tax, liquidity and foreign exchange risks. Performance is calculated for the portfolio, and individual investor performance may differ as a result of trading cost and price paid for investment share. Additional information on the Index, including its performance and tracking error can be viewed on the relevant minimum disclosure document (MDD) on www.sygnia.co.za. A schedule of fees, charges and – where the AMETF engages in securities lending activities, information on such securities lending activities – may be requested via admin@sfs.sygnia.co.za or 0860 794 642. The complete terms and conditions of your AMETF investment are contained in the fund's offering circular, pre-listing statement, programme memorandum and/or supplemental deed, and index constituents with prices are published daily on Sygnia's website. The documents/information may be obtained from www.sygnia.co.za or on request from Sygnia. Nothing in this document shall be considered to state or imply that the fund is suitable for a particular type of investor. All the portfolio options presented are approved collective investment schemes in terms of CISCA. The Manager has the right to close any portfolios to new investors to manage the portfolios more efficiently in accordance with their mandates.

Index disclaimer

The funds or securities referred to herein are not sponsored, endorsed, or promoted by Solactive AG, and Solactive AG bears no liability with respect to any such funds or securities or any index on which such funds or securities are based. The complete terms and conditions of your AMETF Investment are contained in the fund's Offering Circular and Pre-Listing Statement and the relevant Supplement.